Dr. Lonial Discusses Novel Agents in Multiple Myeloma

Sagar Lonial, MD
Published: Tuesday, Apr 03, 2018



Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses novel agents for the treatment of patients with multiple myeloma.

The role of antibodies is still being questioned, according to Lonial. Daratumumab (Darzalex) is beginning to be looked at upfront, as is isatuximab. There are trials looking at histone deacetylase (HDAC) inhibitors as a part of induction therapy, but there were issues with toxicity with that approach, so Lonial is unsure if that will be the optimal drug in the frontline setting. Therapy is going to be moving away from chemotherapy approaches and focusing on the novel agents and antibodies, Lonial adds.

In January 2018, the FDA granted a priority review designation to daratumumab in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.


Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses novel agents for the treatment of patients with multiple myeloma.

The role of antibodies is still being questioned, according to Lonial. Daratumumab (Darzalex) is beginning to be looked at upfront, as is isatuximab. There are trials looking at histone deacetylase (HDAC) inhibitors as a part of induction therapy, but there were issues with toxicity with that approach, so Lonial is unsure if that will be the optimal drug in the frontline setting. Therapy is going to be moving away from chemotherapy approaches and focusing on the novel agents and antibodies, Lonial adds.

In January 2018, the FDA granted a priority review designation to daratumumab in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x